Literature DB >> 3111911

Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.

R Mauler, W Merkle, J Hilfenhaus.   

Abstract

Pasteurization (heat treatment at +60 degrees C for 10 hours in solution) during the production of human plasma protein preparations has proved useful 1. to inactivate a broad spectrum of viruses and 2. in combination with stabilizers to leave the nativity of the products unaffected. Their efficacy has been experimentally tested for HTLV-III/LAV, Hepatitis B and non-A/non-B viruses. The following preparations were tested: with HTLV-III/LAV: Factor VIII, Factor IX, AT III, AHC and PPSB; with Hepatitis B virus: Factor VIII, Factor XIII, AT III, PPSB and Fibrinogen; with Hepatitis non-A/non-B virus: Factor VIII and AT III.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3111911

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  4 in total

Review 1.  Fibrin sealant: a review of its use in surgery and endoscopy.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

3.  Effective inactivation of a wide range of viruses by pasteurization.

Authors:  Albrecht Gröner; Connie Broumis; Randel Fang; Thomas Nowak; Birgit Popp; Wolfram Schäfer; Nathan J Roth
Journal:  Transfusion       Date:  2017-11-16       Impact factor: 3.157

Review 4.  Pathogen safety of plasma-derived products - Haemate P/Humate-P.

Authors:  A Gröner
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.